Laser company nLIGHT (NASDAQ:LASR) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 8.7% year on year to $47.38 million. On the other hand, the company expects next quarter’s revenue to be around $48 million, close to analysts’ estimates. Its non-GAAP loss of $0.30 per share was 51.9% below analysts’ consensus estimates.
Real estate technology company Redfin (NASDAQ:RDFN) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 12% year on year to $244.3 million. On the other hand, next quarter’s revenue guidance of $219.5 million was less impressive, coming in 10.4% below analysts’ estimates. Its GAAP loss of $0.29 per share was 21% below analysts’ consensus estimates.
Medical device company ICU Medical (NASDAQ:ICUI) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 7.1% year on year to $629.8 million. Its non-GAAP profit of $2.11 per share was 42.4% above analysts’ consensus estimates.
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.2% year on year to $774.2 million. Next quarter’s revenue guidance of $770 million underwhelmed, coming in 5.8% below analysts’ estimates. Its non-GAAP profit of $0.64 per share was 10.4% below analysts’ consensus estimates.
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per share was 1.9% below analysts’ consensus estimates.
Health insurance company Clover Health (NASDAQ:CLOV) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 34% year on year to $337 million. Its GAAP loss of $0.04 per share was $0.03 above analysts’ consensus estimates.
Global media and entertainment company iHeartMedia (NASDAQ:IHRT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.8% year on year to $1.12 billion. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $1.10 billion at the midpoint, or 33.7% above analysts’ estimates.
Healthcare services company Astrana Health announced better-than-expected revenue in Q4 CY2024, with sales up 88.4% year on year to $665.2 million. The company expects the full year’s revenue to be around $2.6 billion, close to analysts’ estimates. Its GAAP loss of $0.15 per share was significantly below analysts’ consensus estimates.
Energy drink company Monster Beverage (NASDAQ:MNST) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $1.81 billion. Its non-GAAP profit of $0.38 per share was 5.5% below analysts’ consensus estimates.
Beijing isn't going to allow crypto exchanges to directly operate BTC in China, but there might be a way that Hong Kong crypto ETFs can be traded in the mainland.
